Integra LifeSciences (IART) to Release Quarterly Earnings on Thursday

Integra LifeSciences (NASDAQ:IART) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.80 per share and revenue of $429.62 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Integra LifeSciences Stock Down 2.1%

Shares of NASDAQ IART opened at $11.51 on Wednesday. The firm has a market cap of $896.54 million, a price-to-earnings ratio of -1.78 and a beta of 1.04. The company’s 50-day simple moving average is $12.05 and its 200-day simple moving average is $13.23. The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. Integra LifeSciences has a 52-week low of $10.60 and a 52-week high of $25.45.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Truist Financial reissued a “hold” rating and issued a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Citigroup decreased their price objective on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a report on Friday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a report on Friday, October 31st. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $15.00.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the company. Rubric Capital Management LP grew its stake in shares of Integra LifeSciences by 58.4% in the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after buying an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY grew its position in Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock worth $26,767,000 after acquiring an additional 796,300 shares during the period. Kotler Kevin acquired a new stake in Integra LifeSciences during the fourth quarter worth $5,309,000. Soleus Capital Management L.P. raised its position in Integra LifeSciences by 29.4% in the second quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company’s stock valued at $17,029,000 after purchasing an additional 315,614 shares during the period. Finally, J. Goldman & Co LP lifted its stake in shares of Integra LifeSciences by 30.8% in the 4th quarter. J. Goldman & Co LP now owns 1,243,772 shares of the life sciences company’s stock valued at $15,448,000 after purchasing an additional 292,961 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.